Astragaloside IV

CAS No. 84687-43-4

Astragaloside IV( AS-IV | AST-IV )

Catalog No. M16147 CAS No. 84687-43-4

Astragaloside IV is generally considered to be the primary active ingredient in Astragalus extract,an herbal extract which has been famous for literally thousands of years for its anti-aging properties.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 29 In Stock
10MG 47 In Stock
25MG 69 In Stock
50MG 115 In Stock
100MG 192 In Stock
500MG 482 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Astragaloside IV
  • Note
    Research use only, not for human use.
  • Brief Description
    Astragaloside IV is generally considered to be the primary active ingredient in Astragalus extract,an herbal extract which has been famous for literally thousands of years for its anti-aging properties.
  • Description
    Astragaloside IV is generally considered to be the primary active ingredient in Astragalus extract,an herbal extract which has been famous for literally thousands of years for its anti-aging properties.(In Vitro):Astragaloside IV (10, 20, 40 ng/mL) inhibits NSCLC cell growth, whereas low concentrations of astragaloside IV (1, 2.5, 5 ng/mL) has no obvious cytotoxicity on cell viability. Moreover, combined treatment with astragaloside IV significantly increases chemosensitivity to cisplatin in NSCLC cells. On the molecular level, astragaloside IV co-treatment significantly inhibits the mRNA and protein levels of B7-H3 in the presence of cisplatin. Astragaloside IV inhibits the viability and invasive potential of MDA-MB-231 breast cancer cells, suppresses the activation of the mitogen activated protein kinase (MAPK) family members ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2 and -9. (In Vivo):Astragaloside IV (10, 20 mg/kg, p.o.) exhibits a potent ability to prevent cognitive deficits induced by transient cerebral ischemia and reperfusion. Astragaloside IV (10 mg/kg) and Astragaloside IV (20 mg/kg) can significantly decrease the levels of these cytokines compared to the Model group. Astragaloside IV significantly inhibits the level of TLR4 and its downstream proteins, suggesting that both MyD88-dependent and -independent pathways play important roles in the anti-inflammatory effects of Astragaloside IV. Astragaloside IV attenuates NLRP3 and cleaved-caspase-1 expression, and reduces Iba1 protein expression. In the mice model, the high-dose astragaloside IV group has a significant increase in the 48-hour survival rate [60% (9/15) vs 13.3% (2/15), P < 0.05], significant reductions in the serum ALT and AST levels (P < 0.01), and significant reductions in liver histopathological indices and the degree of apoptosis of hepatocytes (P < 0.01), as well as a significant reduction in the content of MDA in liver homogenate (P < 0.01) and a significant increase in the activity of SOD.
  • In Vitro
    Astragaloside IV (10, 20, 40 ng/mL) inhibits NSCLC cell growth, whereas low concentrations of astragaloside IV (1, 2.5, 5 ng/mL) has no obvious cytotoxicity on cell viability. Moreover, combined treatment with astragaloside IV significantly increases chemosensitivity to cisplatin in NSCLC cells. On the molecular level, astragaloside IV co-treatment significantly inhibits the mRNA and protein levels of B7-H3 in the presence of cisplatin. Astragaloside IV inhibits the viability and invasive potential of MDA-MB-231 breast cancer cells, suppresses the activation of the mitogen activated protein kinase (MAPK) family members ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2 and -9.
  • In Vivo
    Astragaloside IV (10, 20 mg/kg, p.o.) exhibits a potent ability to prevent cognitive deficits induced by transient cerebral ischemia and reperfusion. Astragaloside IV (10 mg/kg) and Astragaloside IV (20 mg/kg) can significantly decrease the levels of these cytokines compared to the Model group. Astragaloside IV significantly inhibits the level of TLR4 and its downstream proteins, suggesting that both MyD88-dependent and -independent pathways play important roles in the anti-inflammatory effects of Astragaloside IV. Astragaloside IV attenuates NLRP3 and cleaved-caspase-1 expression, and reduces Iba1 protein expression. In the mice model, the high-dose astragaloside IV group has a significant increase in the 48-hour survival rate [60% (9/15) vs 13.3% (2/15), P < 0.05], significant reductions in the serum ALT and AST levels (P < 0.01), and significant reductions in liver histopathological indices and the degree of apoptosis of hepatocytes (P < 0.01), as well as a significant reduction in the content of MDA in liver homogenate (P < 0.01) and a significant increase in the activity of SOD.
  • Synonyms
    AS-IV | AST-IV
  • Pathway
    Endocrinology/Hormones
  • Target
    Estrogen Receptor/ERR
  • Recptor
    ERS
  • Research Area
    Other Indications
  • Indication
    ——

Chemical Information

  • CAS Number
    84687-43-4
  • Formula Weight
    784.99
  • Molecular Formula
    C41H68O14
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    C[C@]12CCC34C[C@@]35CCC(O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)C(C)(C)C5[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)CC4[C@]1(C)C[C@@H](O)[C@@H]2[C@@]8(C)CC[C@@H](C(C)(O)C)O8
  • Chemical Name
    (2R,3R,4S,5S,6R)-2-(((2aR,3R,4R,5aS,7R,11aR)-4-hydroxy-3-((2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl)-2a,5a,8,8-tetramethyl-9-(((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)hexadecahydrocyclopenta[a]cyclopropa[e]phenanthren-7-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Shao A, et al. Int J Med Sci. 2014 Aug 8;11(10):1073-81.
molnova catalog
related products
  • AC-186

    AC-186 is a nonsteroidal estrogen receptor β (ERβ) agonist with different affinities for ERβ and ERα, with an EC50 of 6 nM for ERβ and 5000 nM for ERα. AC-186 has neuroprotective activity and has been used in the study of Parkinson's disease.

  • Endoxifen (E-isomer)

    Endoxifen E-isomer is the E-isomer of (Z)-Endoxifen. Endoxifen E-isomer has antiestrogenic effects.

  • Bazedoxifene acetate

    Bazedoxifene acetate (TSE 424; WAY-TES 424), a novel selective estrogen receptor modulator (SERM).